Previous Article | Next Article 
Clinical and Diagnostic Laboratory Immunology, May 1999, p. 405-409, Vol. 6, No. 3
1071-412X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Intranasal Immunization against Dental Caries with
a Streptococcus mutans-Enriched Fimbrial
Preparation
Margherita
Fontana,1,*
Ann J.
Dunipace,1
George K.
Stookey,1 and
Richard
L.
Gregory2,3
Oral Health Research
Institute1 and Departments of Oral
Biology2 and Pathology and Laboratory
Medicine,3 Schools of Dentistry and of
Medicine, Indiana University, Indianapolis, Indiana 46202-5186
Received 1 June 1998/Returned for modification 27 August
1998/Accepted 29 January 1999
 |
ABSTRACT |
Streptococcus mutans has been identified as the major
etiological agent of human dental caries. The first step in the
initiation of infection by this pathogenic bacterium is its attachment
(i.e., through bacterial surface proteins such as glucosyltransferases, P1, glucan-binding proteins, and fimbriae) to a suitable receptor. It
is hypothesized that a mucosal vaccine against a combination of
S. mutans surface proteins would protect against
dental caries by inducing specific salivary immunoglobulin A (IgA)
antibodies which may reduce bacterial pathogenesis and
adhesion to the tooth surface by affecting several adhesins
simultaneously. Conventional Sprague-Dawley rats, infected with
S. mutans at 18 to 20 days of age, were intranasally
immunized with a mixture of S. mutans surface
proteins, enriched for fimbriae and conjugated with cholera toxin B
subunit (CTB) plus free cholera toxin (CT) at 13, 15, 22, 29, and 36 days of age (group A). Control rats were either not
immunized (group B) or immunized with adjuvant alone (CTB and CT
[group C]). At the termination of the study (when rats were 46 days
of age), immunized animals (group A) had significantly (P < 0.05) higher salivary IgA and serum IgG antibody
responses to the mixture of surface proteins and to whole bacterial
cells than did the other two groups (B and C). No significant
differences were found in the average numbers of recovered
S. mutans cells among groups. However, statistically
fewer smooth-surface enamel lesions (buccal and lingual) were detected
in the immunized group than in the two other groups. Therefore, a
mixture of S. mutans surface proteins,
enriched with fimbria components, appears to be a promising
immunogen candidate for a mucosal vaccine against dental caries.
 |
INTRODUCTION |
The first step necessary for
any pathogenic bacterium to initiate infection is its attachment
to a suitable receptor. Several different attachment mechanisms have
been identified for oral bacteria (i.e., through surface proteins, such
as glucosyltransferases [GTF] and glucan-binding proteins, by
sucrose-dependent mechanisms and through surface antigen P1 and/or
fimbriae in sucrose-independent functions). Bacterial fimbriae have
been defined as small (100 to 300 nm), nonflagellar, filamentous,
proteinaceous surface appendages that do not participate in the
transfer of bacterial or viral nucleic acids (1).
Streptococcus mutans has been identified as the major
etiological agent in human dental caries and comprises a significant
percentage of the oral streptococci in carious lesions (16). Fimbriae have been identified on numerous
gram-negative microorganisms as long fibrillar structures but have been
reported for only a limited number of gram-positive microorganisms,
including some oral streptococci, in which they typically
appear as a much shorter fuzzy coat (4, 21). It is our
belief that fimbriae are important virulence factors for S. mutans and are at least partially responsible for
S. mutans sucrose-independent adherence to enamel
surfaces. We have isolated a mixture of S. mutans
surface proteins, which contained fimbria components
(fimbria-enriched preparation), as demonstrated by immunostaining and
electron microscopy, and have elicited antibodies in rabbits against
this preparation (7).
An essential goal in the development of a vaccine for dental caries is
to induce antibodies that block bacterial adhesion and, therefore,
prevent bacterial colonization. This should then affect the formation
of carious lesions. A number of studies with experimental animals and
humans have shown that active and passive immunizations with
S. mutans, either with whole cells or with different cellular components, inhibit S. mutans
colonization and the subsequent formation of dental caries (8,
14, 18, 29). An in vitro microbial model (5) was
used to demonstrate, for the first time, the efficacy of
antibodies against the fimbria-enriched preparation in preventing the
formation of carious lesions (6).
The association of S. mutans soluble cell protein
antigens (e.g., P1) or dextran preparations with cholera toxin (CT) and the B subunit of CT (CTB) has been shown to increase the
immunogenicity (salivary immunoglobulin A [IgA] antibody responses)
of many antigens given perorally, intragastrically, or intranasally
without causing toxic effects (2, 3, 11, 26, 28, 30).
However, only two studies have addressed the role of salivary
antibodies elicited intranasally by an antigen linked to CTB in
protection against dental caries (9, 10). CT is an
exceptionally immunogenic antigen. This is attributed to the
immunopotentiating (or adjuvant) property of CT, as well as to the
ability of nontoxic CTB to bind to cell surface GM1
ganglioside and act as a carrier protein (3, 26).
The purpose of this study was to test the hypothesis that conventional
rats which are intranasally immunized with a mixture of
fimbria-enriched preparation of S. mutans surface
proteins conjugated with CTB exhibit a higher salivary IgA
response to the fimbria-enriched preparation, have fewer
S. mutans organisms adhered to the teeth, and develop
fewer caries than do control animals. The combination of surface
antigens used as the immunogen in this study was expected to elicit a
mucosal immune response that would affect S. mutans
cariogenicity by inhibiting several adhesion mechanisms simultaneously.
 |
MATERIALS AND METHODS |
Vaccine preparation.
The isolation of a mixture of
S. mutans surface proteins enriched for fimbria
components has been previously described by Fontana et al.
(7). Furthermore, Perrone et al. (23)
characterized two of the bands seen in the mixed protein preparation as
GTF and P1. In this study, we isolated a mixture of fimbria-enriched proteins from S. mutans A32-2 (serotype c) by using a
10 mM sodium phosphate saline solution (pH 7.2), containing 1 mM
CaCl2 and 1 mM phenylmethylsulfonyl fluoride (fimbria buffer).
The fimbria-enriched preparation was chemically conjugated to CTB as
previously described (11, 25, 26, 30). Briefly, equal
amounts of fimbria-enriched preparation and low-salt CTB (List
Biological Laboratories, Inc., Campbell, Calif.) were coupled by using
N-succinimidyl-(3-[2-pyridyl]-dithio)propionate (SPDP) (Pharmacia LKB Biotechnology, Piscataway, N.J.). The precipitate that
formed in the CTB derivative was dissolved by adding 10 µl of
ethanolamine (Sigma Chemical Company, St. Louis, Mo.), and both
preparations were dialyzed separately against 0.01 M phosphate-buffered saline (pH 7.4) overnight at 4°C, to remove excess SPDP. The fimbriae derivative was reduced with 50 mM dithiothreitol (Pharmacia) for 30 min
at room temperature, passed over a Sephadex G-25 column (Pharmacia),
added to the unreduced CTB derivative, and kept overnight at 4°C. The
final conjugate was dialyzed against phosphate-buffered saline (0.01 M,
pH 7.4) and stored in aliquots at
80°C. Enzyme-linked immunosorbent
assay (ELISA) of plates coated with GM1 ganglioside (Sigma)
followed by the vaccine conjugate and probed with antibodies to CTB and
the fimbria-enriched preparation demonstrated that both the receptor
binding ability of CTB and the antigenicity of the fimbria-enriched
preparation were preserved in the conjugate.
General experimental design.
The study had three groups
labeled A, B, and C. Twenty-eight conventional rats (Harlan
Sprague-Dawley) were used per group. From their arrival in our
laboratory, the dams and pups were given Diet MIT 305 (containing 5%
sucrose) and deionized water ad libitum until the pups were weaned (18 days old). The animals were then provided Diet MIT 200 (containing 67%
sucrose) ad libitum throughout the challenge period (18 to 46 days old).
Group A was intranasally given an S. mutans
fimbria-enriched preparation-CTB vaccine (50 µg, containing 37.5 µg of fimbria-enriched preparation and 12.5 µg of CTB) together
with a small dose (5 µg) of free (azide-free) CT (List Biological)
with a pipettor adapted with a sterile tip, on day 13 of age and again
on days 15, 22, 29, and 36. The dose volume was divided between the two nostrils (14 µl in each) and administered twice. Five days after the
first immunization (at 18 days of age) the rat pups were challenged with 0.2 ml of an overnight, stationary-phase culture of
streptomycin-resistant S. mutans A32-2 serotype c
(108 CFU/ml) for three consecutive days (18, 19, and 20 days of age). This involved placing 0.1 ml of the S. mutans culture on the occlusal surfaces of each of the mandibular
molar quadrants (for a total of 0.2 ml of culture/animal) with a
1,000-µl micropipettor. Colonization was confirmed at day 25 of age
(5 days after the last bacterial challenge) by culturing oral swab
samples on mitis salivarius agar supplemented with streptomycin (0.04 g/ml) (MS-S). The test isolate (S. mutans A32-2) used
in this study was made streptomycin resistant by stepwise isolation on
MS-S. Stability of the streptomycin resistance was tested by
passaging the culture for 12 consecutive days in Todd-Hewitt broth
without streptomycin and plating on MS-S plates on days 6 and 12.
Group B served as a positive unimmunized control and was challenged
with S. mutans A32-2 at days 18 through 20 but did not receive the fimbria-enriched preparation-CTB vaccine. Group C was
infected and received the CTB (12.5 µg) and CT (5 µg) adjuvants only.
The animals were euthanatized at 46 days of age during blood collection
by intracardiac puncture. Death was verified by the detection of
pneumothorax. Saliva and serum samples were collected to determine the
levels of salivary IgA and serum IgG antibody to S. mutans A32-2 whole cells, the S. mutans A32-2
fimbria-enriched preparation, and CTB as described below. Following
termination, the right mandibular hemijaw quadrant of each rat was
placed in a tube containing 3 ml of sterile saline. Plaque was
disrupted from the molar surfaces by vortexing for 20 s, followed
by sonication for 20 s at a setting of 20 (50 Sonic Dismembrator;
Fisher), and finally vortexing again for 20 s. The number of
S. mutans cells adhered to the teeth on one hemijaw
quadrant was determined by culturing undiluted and 1:10-diluted
(double-plated) aliquots of each sample by using a spiral plater
(Spiral Systems) on MS-S plates and incubating the plates at 37°C in
5% CO2 and 95% air for 72 h. All four hemijaws were
then stained overnight with a murexide (Sigma) solution (0.3 g of
murexide, 300 ml of distilled H2O, and 700 ml of ethanol)
for caries scoring. The jaws were rinsed, allowed to dry, examined for
smooth-surface caries, sectioned, and then microscopically examined for
sulcal and interproximal caries by using the Keyes method (12,
22).
Collection of saliva and serum samples.
At the termination
of the study, the rats were injected intramuscularly with
ketamine-xylazine (9:5 vol/vol; 0.14 ml/100 g of body weight), and
individual saliva samples (approximately 1 ml/animal) were collected
with a capillary Pasteur pipette after pilocarpine stimulation over a
15-min interval. Pilocarpine (5 µg/ml in sterile saline; 0.1 ml/100 g
of body weight) was given intraperitoneally between 3 and 5 min after
anesthesia. The saliva samples were centrifuged (735 × g for 30 min, 4°C) and stored at
20°C until assayed for IgA
antibody activity against S. mutans whole cells, the
fimbria-enriched preparation, and CTB by using ELISA as described
below. After the collection of saliva, all available blood was
collected by cardiac puncture, allowed to clot at room temperature for
1 h, and stored overnight at 4°C. Serum was separated from the
clot by centrifugation (3,210 × g for 30 min, 4°C)
and stored at
20°C until it was assayed for IgG antibody activity
by ELISA.
Determination of antibody activities against the fimbria-enriched
preparation, whole cells, and CTB by ELISA.
Polystyrene microtiter
plates (Linbro; Flow Laboratories, Inc., McLean, Va.) were coated (100 µl/well) with either the fimbria-enriched preparation (1 µg/ml
diluted in 0.1 M carbonate-bicarbonate buffer, pH 9.6),
formaldehyde-killed bacteria (diluted to an optical density at 540 nm
of 0.5 in carbonate-bicarbonate buffer), or CTB (1 µg/ml diluted in
carbonate-bicarbonate buffer) and incubated at 37°C for 3 h.
Coated plates were washed three times in Tween-saline (TS) (0.9% NaCl
containing 0.05% Tween 20) to remove unbound antigen. Free sites on
the plates were blocked by reaction for 1 h with 200 µl of a
solution containing 10 µg of bovine serum albumin (Sigma) per ml at
25°C. Diluted rat serum or saliva samples (diluted 1:100 or 1:10,
respectively, in TS) were added (100 µl/well) to the wells, in
triplicate, and the plates were incubated for 2 h at 37°C.
Antigen added without serum or saliva, but with TS, served as the
negative control. A saliva or serum sample from an immunized rat
(group A) served as a reference control. The plates were washed three
times with TS and incubated for 3 h at 37°C with 100 µl of a
reagent specific for the heavy chain of either horseradish
peroxidase-labeled anti-rat IgA (for saliva samples) or IgG (for serum
samples) (1:1,000; Sigma) per well. After the plates were washed three
times with TS, orthophenylenediamine dihydrochloride (0.5 mg/ml) in
0.05 M citrate buffer (pH 5.0) containing 0.7 µl of 30%
H2O2/ml of substrate was added (100 µl) to
every well. Color development was monitored between 10 and 30 min, and
the reaction was stopped with 2 N H2SO4 (100 µl/well). The amount of color that developed in the microtiter
plate was measured at 490 nm with a Titertek Multiscan
spectrophotometer (Flow). The background values were automatically
subtracted from the values for the experimental samples. The data were
reduced by computing the means and standard errors of the means (SEM) of the absorbances of each sample, determined in triplicate.
Determination of antibody specificity to the fimbria-enriched
preparation by electrophoretic techniques.
To confirm antibody
specificity to fimbria-associated components, the fimbria-enriched
preparation was electrophoresed by reducing sodium dodecyl
sulfate-10% polyacrylamide gel electrophoresis. Molecular weight
standards were included in the gel (Rainbow colored protein molecular
weight markers; Amersham, Arlington Heights, Ill.). Proteins were
transferred electrophoretically to nitrocellulose paper for
immunoblotting. Two blots were prepared. Each blot was cut into strips
with a sharp scalpel, so that it could be probed with saliva or serum
from different groups. Strips from one blot were each probed with the
pooled serum (diluted 1:50) from rats in either group A, B, or C
(adjuvant), while strips from the second blot were each probed with the
pooled saliva (diluted 1:4) from rats in either group A, B, or C. Negative control strips from both blots were incubated with washing
buffer (Trizma base, NaCl, Tween-20 [pH 7.4]). Proteins which reacted
with serum antibodies were visualized on nitrocellulose by alkaline
phosphatase-labeled anti-rat IgG heavy chain antibody (Sigma) followed
by nitroblue tetrazolium-5-bromo-4-chloro-3-indolylphosphate
(NBT-BCIP) (Bio-Rad Laboratories, Richmond, Calif.). Proteins which
reacted with salivary antibodies were visualized on nitrocellulose by
applying anti-rat IgA biotin-labeled antibody (Zymed Laboratories Inc.,
San Francisco, Calif.) followed by alkaline phosphatase-labeled
ExtrAvidin (Sigma) and NBT-BCIP. Molecular weights and percentages of
total antibody binding were determined by comparison to protein
standards with an UltroScan XL laser densitometer and GelScan XL
software (Pharmacia).
Data analysis.
Means and variances were calculated for each
measured parameter and treatment group. If the variances of any of the
response variables appeared to be unequal, an appropriate
transformation (e.g., logarithmic or square root) was done prior to
analysis. The statistical analysis of ELISA salivary IgA and serum IgG
antibody data, bacterial numbers, and smooth-surface and total
smooth-surface caries scores was done on the logarithmic scale because
the means and standard deviations had a positive association (i.e.,
standard deviations increased as the means increased). However,
original scores were used in all tables for presentation purposes. The caries scores, antibody data, and bacterial counts were analyzed with
separate single-factor analysis-of-variance models. A multiple-factor analysis-of-variance model was used to compare the treatment groups for
differences in caries measurements. The type of experimental or control
group was assigned as the fixed effect, and litter was designated the
random effect. Multiple comparisons were made by using Tukey's method
at a 95% overall confidence level.
 |
RESULTS |
In general, the group A animals demonstrated significantly
increased (P < 0.05) levels of IgA and IgG antibodies
in saliva and serum, respectively (Tables
1 and 2),
against the S. mutans A32-2 surface proteins,
fimbria-enriched preparation, and whole cells. Significantly
higher levels of antibodies against CTB were present in the
saliva of all group A rats. The immunoblot of the S. mutans fimbria-enriched preparation probed with the pooled saliva
from group A rats demonstrated only two bands, at approximately 59 and
190 kDa (Fig. 1), while the immunoblot
probed with the pooled serum from group A rats demonstrated only
one band, at 59 kDa. The band at 59 kDa is believed to be a
fimbrial component, distinct from Smith and Taubman's 59-kDa
glucan-binding protein (reference 27 and unpublished
data), whose role is currently being investigated; the band seen at 190 kDa has been previously shown to be P1 (23).
Negative-control blot strips for both serum- and saliva-probed blots,
as well as strips probed with saliva or serum from group B rats, showed
no response. The blot strip probed with serum from group C rats showed
no response, while the strip probed with saliva from group C rats
showed very faint bands at 190 and 66 kDa.

View larger version (82K):
[in this window]
[in a new window]
|
FIG. 1.
Representative immunoblot of S. mutans
A32-2 fimbria-enriched preparation probed with the pooled saliva from
rats in group A, followed by anti-rat IgA biotin-labeled antibody,
alkaline phosphatase-labeled ExtrAvidin, and NBT-BCIP. Numbers at the
right are molecular masses, in kilodaltons.
|
|
The increase in antibodies to the fimbria-enriched preparation did not
result in a decrease of bacteria adhered to the teeth, since the three
groups were not significantly different from each other. The
S. mutans A32-2 plaque counts (mean ± SEM) for
groups A, B, and C were (6.62 ± 5.24) × 104,
(8.85 ± 3.52) × 104, and (5.16 ± 2.11) × 104 CFU/ml, respectively. The obtained P values
were 0.3760 for group A versus B, 0.6588 for group A versus C,
and 0.8857 for group B versus C. On the other hand, significantly
fewer smooth-surface enamel lesions (Table
3) were detected in group A rats than in animals from the other two groups. No significant difference was found
between groups B and C. Group A rats had the lowest total-enamel caries
scores of the three groups analyzed (Table
4). However, there were no significant
differences in carious lesions in the interproximal or sulcal enamel or
in the dentin among the treatment groups.
 |
DISCUSSION |
Our laboratory has been extensively involved in establishing the
role S. mutans fimbriae play in adherence to and
colonization of the tooth surface by this bacterium and testing if
antibodies against S. mutans fimbria components reduce
the adherence of S. mutans to the tooth surface,
thereby inhibiting the development of primary dental caries (6,
23, 24). Caries-free (CF) adult individuals have higher levels of
salivary IgA antibodies to fimbria-enriched preparation of
S. mutans than do caries-active (CA) individuals
(7). These results suggest that CF subjects may be protected
immunologically from dental caries in part by salivary IgA antibody
against S. mutans fimbrial antigens. Perrone et
al. (23) demonstrated, with immunoblot analyses
and ELISA techniques with antibody to fimbria-enriched preparations,
GTF, and P1 antigen, that the levels of fimbria components, GTF, and P1
antigen were higher in fimbria-enriched preparations from
S. mutans isolates from CA subjects than in
preparations from CF individuals. These results suggest that the
differences between the composition of S. mutans
fimbriae in isolates from CA and CF subjects may play an important role
in the virulence of this microorganism in dental caries. Our laboratory
has also reported that a 52-kDa salivary protein, identified as
amylase, is the major protein in human saliva which binds
S. mutans fimbria-enriched preparations
(24). In addition, results obtained with an in vitro
bacterial model demonstrated the efficacy of antibodies against
S. mutans fimbria-enriched surface components in
decreasing caries development (6).
Decisions regarding the use of a conventional, rather than a
gnotobiotic, rat model and the immunization regimen used in this study
were partially based on the intranasal CTB vaccine study of Katz et al.
(11). Although they demonstrated that the magnitude of the
salivary IgA response in conventional animals was significantly lower
than that in gnotobiotic rats, antibody levels increased in
conventional rats after the second and third immunizations and reached
their highest titers after the fourth immunization. Wu and Russell
(30) have also demonstrated that mice required three
immunizations before substantial elevations of antibody levels were
obtained; however, monkeys responded after the second immunization
(25). Furthermore, in the study by Katz et al. (11), immunized conventional rats had a 38% reduction of
S. mutans cells in their plaque and a 64% reduction in
buccal-enamel caries activity, and the levels of caries activity on
sulcal surfaces were also significantly reduced, supporting the
effectiveness of an intranasal CTB vaccine in these rats. In addition,
since the conventional rat model is more similar to humans, it was
selected for use in the present study. However, our data failed to
demonstrate a decrease in the number of S. mutans cells
adhered to the teeth or a statistically significant decrease in caries
score categories in the vaccinated group other than smooth surfaces
(e.g., sulcal caries and interproximal caries). A possible significant
difference between our study and that of Katz et al. (11)
was that the latter coupled a single protein (antigen I/II [AgI/II])
to CTB, while a combination of proteins (fimbria-enriched preparation) was coupled to CTB in the present study. This may have led to a
dilution of immunoprotective antigens coupled to CTB, which was not
expected initially. Alternatively, the coupling technique may not have
been as effective. In rhesus monkeys, the coupling or mixing
of antigen with CTB seemed not to make a great difference (25). The fact that intranasal immunization is an effective route for generating mucosal immune responses in the nonhuman primate,
particularly when the vaccine includes CTB, is promising for humans
(25).
In addition, although the immunization protocol in this study was
similar to that of Katz et al. (11), the rats used in this
investigation were much younger when antigen administration began. This
might have affected the animals' immunocompetence status at the
beginning of the study. Michalek et al. (20) demonstrated that significant antibody responses occurred in the saliva of gnotobiotic rats 5 or 6 days after gastric intubation of S. mutans. However, those animals were initially immunized at 19 days
of age. The results obtained by Michalek et al. (20) clearly
indicated that local antibodies were present in the saliva at the time
of S. mutans challenge (i.e., 5 days after initial
immunization). Based on this, conventional rats in the present study
were immunized 5 days prior to bacterial challenge. Because the first
and second molars of the rat erupt between 16 and 21 days of age,
animals are usually challenged with cariogenic bacteria when they are between 19 and 24 days of age (19). After tooth eruption,
enamel maturation occurs and indigenous plaque microorganisms colonize the teeth, which then become more resistant to specific bacterial colonization and to caries attack. If Harlan Sprague-Dawley rats (the
rat model used for this experiment) are not challenged with a
cariogenic strain of bacteria at the time their molars erupt, they will
not develop any significant caries in the study time frame, even if put
on a highly cariogenic diet. Additionally, the superinfection at the
time of molar eruption ensures the colonization of the surface of the
newly erupted tooth mainly with the superinfecting bacteria, so
that the colonization of the teeth by indigenous bacteria is
greatly decreased. However, although the potential role of the
indigenous flora in caries development is greatly minimized, it should
not be completely ignored. The first two immunizations in the present
study were done anticipating the presence of antifimbria antibodies in
saliva during mineralization of the newly erupted molars.
Theoretically, the antibodies, by binding the bacteria and inhibiting
colonization, could block the subsequent attachment of S. mutans A32-2 to the teeth. In mice, at least two to three
intragastric doses of more than 15 µg of AgI/II coupled to CTB plus
free CT were required to induce salivary IgA antibody responses, which
peaked at 35 days and persisted at lower levels for 5 to 6 months
(26). However, the use of 50 µg of AgI/II produced maximal
responses (26) and was effective in eliciting protection
against dental caries in rats (11). Therefore, we decided to
use a similar dose in this study.
Salivary IgA and serum IgG antibody levels were significantly increased
in the vaccinated group. These data indicated that the immunization
protocol used was effective in producing a mucosal and systemic immune
response against an S. mutans fimbria-enriched surface
protein preparation and, therefore, whole cells which have these same
cell surface components. This is not surprising, since the immunization
regimen with CTB and CT is known to result not only in mucosal
responses but also in systemic responses (3). Previous
studies with mice (30) and monkeys (25)
intranasally immunized with AgI/II coupled to CTB demonstrated that
this route was highly effective at inducing secretory IgA in saliva and
other secretions, as well as IgG in plasma. However, the previous
studies did not investigate the level of antibodies sufficient to
protect against dental caries. Furthermore, intranasal immunization has been reported to induce stronger antibody responses in saliva and
serum than does intragastric immunization (30). A possible explanation is that intranasal cavities contain fewer proteolytic enzymes than the intestinal lumen; therefore, antigen administered intranasally may be more effective at stimulating the mucosal immune system than comparable amounts of antigen delivered by the
intragastric route (30). Although it is known that
immunization protocols which elicit only salivary IgA antibodies are
successful in reducing dental caries (18), parenteral
immunization, in which serum IgG is the main antibody elicited,
has also been shown to confer partial immunity against dental
caries (15). Therefore, eliciting both mucosal and
systemic responses may be beneficial (3). While IgA
antibody would offer protection against a mucosal pathogen by
preventing colonization at the mucosal surface, serum IgG antibody
might act against organisms that evade the mucosal defenses and invade
the tissues or colonize subgingival sites. The immunoblot results
demonstrate that antibodies against the 59-kDa protein were
successfully elicited in both saliva and serum. Furthermore, pooled
saliva from group A rats strongly reacted with purified 59-kDa protein
during immunoblotting (data not shown). However, antibodies were also
elicited against P1 in saliva. This is not surprising, since it has
been suggested that P1 forms part of the fimbriae (or fuzzy coat)
surrounding S. mutans cells, since P1 mutants lack a
fuzzy coat (13). P1 has been shown to be protective (11); future studies will address the role of the 59-kDa
protein. Therefore, in the present study, salivary antibodies were
directed against a mixture of S. mutans surface
proteins and were expected to offer better protection than each antigen
alone. It was evident that the amount of antibodies elicited in this
study was not sufficient to produce an overwhelming reduction in all
caries scores. However, the data for smooth-surface caries definitely
indicated a trend in caries reduction in the vaccinated group. The fact
that antibodies were not protective against sulcal caries may be a
consequence of sulcal anatomy and the inaccessibility of sulci to
antibodies. That specific salivary IgA antibodies might affect bacteria
not only by agglutinating them but also by neutralizing enzyme
activities (17) may explain the effect seen on caries in
spite of no observable reduction in the number of adherent bacteria.
Another possible explanation is that enumerated bacteria were recovered
from various sites, but caries protection was observed only for
specific sites. Site-specific sampling might have shown a difference in
colonization. The present study demonstrated that either the dose of
fimbria-enriched preparation used has to be increased or the
immunization protocol used has to be changed in future studies in order
to increase the level of caries-protective antibodies.
Dietary factors critically influence the composition and
pathogenic potential of S. mutans-infected animal
models by affecting the implantation, colonization, and metabolic
virulence of the bacterium. Sucrose has been demonstrated to be
extremely cariogenic and to support rapidly progressive pathogenesis
(10). In the present study, mean weight gains among
treatment groups were not significantly different, indicating
that all groups consumed the same amount of food and that none of
the treatment regimens had an adverse effect on growth. However,
the presence of such a large amount of dietary sucrose (67%) probably
supported the action of GTF in mainly inducing a glucan-adhered plaque.
This may additionally explain why no differences in the numbers of
bacteria were observed among the treatment groups in this study,
although an antibody effect on cell surface protein or
sucrose-independent attachment was anticipated. Future investigators
should consider using a diet lower in sucrose.
The ultimate goal in the prevention of bacterial adhesion is a
long-lasting protection conferred by an appropriate vaccine. A mixture
of S. mutans surface proteins, enriched with fimbria components, coupled to CTB was used in this study. It was concluded that the intranasal immunization route successfully raised antibody levels in the saliva and serum of vaccinated rats, which was
subsequently reflected in a decrease in smooth-surface caries scores.
However, further studies are being conducted to characterize and
sequence the 59-kDa protein and to compare the effect of specific
antibodies to this protein to the effects of antibodies to P1 or a
mixture of both proteins.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Oral Health
Research Institute, 415 Lansing St., Indianapolis, IN 46202. Phone: (317) 274-5626. Fax: (317) 274-5425. E-mail:
MFONTANA{at}IUSD.IUPUI.EDU.
 |
REFERENCES |
| 1.
|
Bakaletz, L. O.,
B. M. Tallan,
T. Hoepf,
T. F. DeMaria,
H. G. Birck, and D. J. Lim.
1988.
Frequency of fimbriation of nontypable Haemophilus influenzae and its ability to adhere to chinchilla and human respiratory epithelium.
Infect. Immun.
56:331-335[Abstract/Free Full Text].
|
| 2.
|
Bergquist, C.,
T. Lagergård,
M. Lindblad, and J. Holmgren.
1995.
Local and systemic antibody responses to dextran-cholera toxin B subunit conjugates.
Infect. Immun.
63:2021-2025[Abstract].
|
| 3.
|
Czerkinsky, C.,
M. W. Russell,
N. Lycke,
M. Lindblad, and J. Holmgren.
1989.
Oral administration of a streptococcal antigen coupled to cholera toxin B subunit evokes strong antibody responses in salivary glands and extramucosal tissues.
Infect. Immun.
57:1072-1077[Abstract/Free Full Text].
|
| 4.
|
Fachon-Kalweit, S.,
B. L. Elder, and P. Fives-Taylor.
1985.
Antibodies that bind to fimbriae block adhesion of Streptococcus sanguis to saliva-coated hydroxyapatite.
Infect. Immun.
48:617-624[Abstract/Free Full Text].
|
| 5.
|
Fontana, M.,
A. J. Dunipace,
R. L. Gregory,
T. W. Noblitt,
Y. Li,
K. K. Park, and G. K. Stookey.
1996.
An in-vitro microbial model for studying secondary caries formation.
Caries Res.
30:112-118[Medline].
|
| 6.
| Fontana, M., T. L. Buller, A. J. Dunipace,
G. K. Stookey, and R. L. Gregory. 1998. Unpublished
data.
|
| 7.
|
Fontana, M.,
L. E. Gfell, and R. L. Gregory.
1995.
Characterization of preparations enriched for Streptococcus mutans fimbriae: salivary immunoglobulin A antibodies in caries-free and caries-active subjects.
Clin. Diagn. Lab. Immunol.
2:719-725[Abstract].
|
| 8.
|
Gregory, R. L.,
S. M. Michalek,
I. L. Shechmeister, and J. R. McGhee.
1983.
Effective immunity to dental caries: protection of gnotobiotic rats by local immunization with a ribosomal preparation from Streptococcus mutans.
Microbiol. Immunol.
27:787-800[Medline].
|
| 9.
|
Hajishengallis, G.,
M. W. Russell, and S. M. Michalek.
1998.
Comparison of an adherence domain and a structural region of Streptococcus mutans antigen I/II in protective immunity against dental caries in rats after intranasal immunization.
Infect. Immun.
66:1740-1743[Abstract/Free Full Text].
|
| 10.
|
Hamada, S., and H. D. Slade.
1980.
Biology, immunology, and cariogenicity of Streptococcus mutans.
Microbiol. Rev.
44:331-384[Free Full Text].
|
| 11.
|
Katz, J.,
C. C. Harmon,
G. P. Buckner,
G. J. Richardson,
M. W. Russell, and S. M. Michalek.
1993.
Protective salivary immunoglobulin A responses against Streptococcus mutans infection after intranasal immunization with S. mutans antigen I/II coupled to the B subunit of cholera toxin.
Infect. Immun.
61:1964-1971[Abstract/Free Full Text].
|
| 12.
|
Keyes, P. H.
1958.
Dental caries in the molar teeth of rats. II. A method for diagnosing and scoring several types of lesions simultaneously.
J. Dent. Res.
37:1088-1099[Abstract/Free Full Text].
|
| 13.
|
Lee, S. F.,
A. Progulske-Fox,
G. W. Erdos,
D. A. Piacentini,
G. Y. Ayakawa,
P. J. Crowley, and A. S. Bleiweis.
1989.
Construction and characterization of isogenic mutants of Streptococcus mutans deficient in major surface protein antigen P1 (I/II).
Infect. Immun.
57:3306-3313[Abstract/Free Full Text].
|
| 14.
|
Lehner, T.,
J. Caldwell, and R. Smith.
1985.
Local passive immunization by monoclonal antibodies against streptococcal antigen I/II in the prevention of dental caries.
Infect. Immun.
50:796-799[Abstract/Free Full Text].
|
| 15.
|
Lehner, T.,
M. W. Russell,
J. Caldwell, and R. Smith.
1981.
Immunization with purified protein antigens from Streptococcus mutans against dental caries in rhesus monkeys.
Infect. Immun.
34:407-415[Abstract/Free Full Text].
|
| 16.
|
Loesche, W. J., and L. H. Straffon.
1979.
Longitudinal investigation of the role of Streptococcus mutans in human fissure decay.
Infect. Immun.
26:498-507[Abstract/Free Full Text].
|
| 17.
|
McGhee, J. R., and J. Mestecky.
1983.
The secretory immune system.
Ann. N. Y. Acad. Sci.
409:1-896.
|
| 18.
|
Michalek, S. M.,
J. R. McGhee,
J. Mestecky,
R. R. Arnold, and L. Bozzo.
1976.
Ingestion of Streptococcus mutans induces secretory immunoglobulin A and caries immunity.
Science
192:1238-1240[Abstract/Free Full Text].
|
| 19.
|
Michalek, S. M.,
J. R. McGhee, and J. M. Navia.
1975.
Virulence of Streptococcus mutans: a sensitive method for evaluating cariogenicity in young gnotobiotic rats.
Infect. Immun.
12:69-75[Abstract/Free Full Text].
|
| 20.
|
Michalek, S. M.,
I. Morisaki,
C. C. Harmon,
S. Hamada, and J. R. McGhee.
1983.
Effective immunity to dental caries: gastric intubation of Streptococcus mutans whole cells or cell walls induces protective immunity in gnotobiotic rats.
Infect. Immun.
39:645-654[Abstract/Free Full Text].
|
| 21.
|
Morris, E. J.,
N. Ganeshkumar,
M. Song, and B. C. McBride.
1987.
Identification and preliminary characterization of a Streptococcus sanguis fibrillar glycoprotein.
J. Bacteriol.
169:164-171[Abstract/Free Full Text].
|
| 22.
|
Navia, J. M.
1977.
Experimental dental caries, p. 257-297.
In
J. M. Navia (ed.), Animal models in dental research. University of Alabama Press, Birmingham.
|
| 23.
|
Perrone, M.,
L. E. Gfell,
M. Fontana, and R. L. Gregory.
1997.
Antigenic characterization of fimbria preparations from Streptococcus mutans isolates from caries-free and caries-susceptible subjects.
Clin. Diagn. Lab. Immunol.
4:291-296[Abstract].
|
| 24.
|
Ray, C. A.,
L. E. Gfell,
T. L. Buller, and R. L. Gregory.
1999.
Interactions of Streptococcus mutans fimbria-associated surface proteins with salivary components.
Clin. Diagn. Lab. Immunol.
6:400-404[Abstract/Free Full Text].
|
| 25.
|
Russell, M. W.,
Z. Moldoveanu,
P. L. White,
G. J. Sibert,
J. Mestecky, and S. M. Michalek.
1996.
Salivary, nasal, genital, and systemic antibody responses in monkeys immunized intranasally with a bacterial protein antigen and the cholera toxin B subunit.
Infect. Immun.
64:1272-1283[Abstract].
|
| 26.
|
Russell, M. W., and H.-Y. Wu.
1991.
Distribution, persistence, and recall of serum and salivary antibody responses to peroral immunization with protein antigen I/II of Streptococcus mutans coupled to the cholera toxin B subunit.
Infect. Immun.
59:4061-4070[Abstract/Free Full Text].
|
| 27.
|
Smith, D. J., and M. A. Taubman.
1996.
Experimental immunization of rats with a Streptococcus mutans 59-kilodalton glucan-binding protein protects against dental caries.
Infect. Immun.
64:3069-3073[Abstract].
|
| 28.
|
Takahashi, I.,
N. Okahashi,
T. Kanamoto,
H. Asakawa, and T. Koga.
1990.
Intranasal immunization of mice with recombinant protein antigen of serotype c Streptococcus mutans and cholera toxin B subunit.
Arch. Oral Biol.
35:475-477[Medline].
|
| 29.
|
Taubman, M. A., and D. J. Smith.
1976.
Effects of local immunization with glucosyltransferase fractions from Streptococcus mutans on dental caries in rats and hamsters.
J. Immunol.
118:710-716[Abstract/Free Full Text].
|
| 30.
|
Wu, H.-Y., and M. W. Russell.
1993.
Induction of mucosal immunity by intranasal application of a streptococcal surface protein antigen with the cholera toxin B subunit.
Infect. Immun.
61:314-322.
|
Clinical and Diagnostic Laboratory Immunology, May 1999, p. 405-409, Vol. 6, No. 3
1071-412X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
MURDOCH-KINCH, C. A., McLEAN, M. E.
(2003). Minimally invasive dentistry. Journal of the American Dental Association
134: 87-95
[Abstract]
[Full Text]
-
Smith, D.J.
(2002). DENTAL CARIES VACCINES: PROSPECTS AND CONCERNS. Crit. Rev. Oral Biol. Med.
13: 335-349
[Abstract]
[Full Text]
-
Mettens, P., Monteyne, P.
(2002). Life-style vaccines. Br Med Bull
62: 175-186
[Abstract]
[Full Text]
-
Fontana, M., Buller, T. L., Dunipace, A. J., Stookey, G. K., Gregory, R. L.
(2000). An In Vitro Microbial-Caries Model Used to Study the Efficacy of Antibodies to Streptococcus mutans Surface Proteins in Preventing Dental Caries. CVI
7: 49-54
[Abstract]
[Full Text]
-
Ray, C. A., Gfell, L. E., Buller, T. L., Gregory, R. L.
(1999). Interactions of Streptococcus mutans Fimbria-Associated Surface Proteins with Salivary Components. CVI
6: 400-404
[Abstract]
[Full Text]